TABLE 3.
Mumps virus-specific IgG titers and avidities of individuals vaccinated against mumps
| Case no. | Age (yr)/sexa | Daysb | IgMc | IgG
|
|
|---|---|---|---|---|---|
| Titer (102) | Avidity (%) | ||||
| V-1 | 1/F | 20 | Neg | NDd | |
| V-1 | 1/F | 45 | Pos | 16 | 1 |
| V-2 | 4/F | 31 | NT | 4 | 3 |
| V-3 | 3/M | 34 | NT | 6 | 1 |
| V-4 | 4/F | 75 | NT | 14 | 1 |
| V-4 | 4/F | 90 | NT | 18 | 2 |
| V-5 | 7/F | 166 | Neg | 12 | 0 |
| V-5 | 7/F | 237 | Neg | 21 | 16 |
| V-6 | 2/M | 349 | NT | 6 | 16 |
| V-7 | 1/M | 36 (19)e | Pos | 231 | 28 |
a
M, male; F, female.
b
The day of vaccination was designated day 0.
c
Neg, negative; Pos, positive; NT, not tested.
d
ND, not detectable.
e
This patient developed parotid gland swelling 17 days after vaccination. Day 19 was counted from the onset of disease. The Urabe mumps vaccine virus was detected in the cerebrospinal fluid by PCR.